Did you mean 1,5 10 7?
Displaying drugs 2951 - 2975 of 4316 in total
Amrubicin
Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January...
Investigational
Matched Iupac: … (7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy}-6,11-dihydroxy-5,7,8,9,10,12-hexahydrotetracene …
SB-743921
Investigational
Matched Iupac: … N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-4H-chromen-2-yl)-2-methylpropyl]-4-methylbenzamide …
TAK-751S
TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic Escherichia coli.
Investigational
UX701
Investigational
Alvocidib
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
Experimental
Investigational
Methylcantharidimide
Methylcantharidimide is under investigation in clinical trial NCT03996681 (TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma).
Investigational
Cinaciguat
Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)).
Investigational
Matched Description: … (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 …
Gibberellin A4
Experimental
Quercetin-3'-O-phosphate
Quercetin-3'-O-phosphate has been used in trials studying the treatment of Insulin Resistance and Impaired Glucose Tolerance.
Investigational
KC706
KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.
Investigational
SB-705498
SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.
Investigational
CP-724714
CP-724,714 has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasm Metastasis.
Investigational
Ro 24-7429
Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).
Investigational
Matched Iupac: … 7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine …
TST10088
TST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating proteins. These molecules efficiently kill cells by activating preprogrammed death pathways known as apoptosis. TST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by...
Investigational
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
CP-744809
Experimental
Ro 12-7310
Experimental
SB-773812
SB-773812 is under investigation in clinical trial NCT00259870 (SB-773812 Administered in Adults With Schizophrenia).
Investigational
Matched Iupac: … 7-{4-[(4-chlorophenyl)methoxy]benzenesulfonyl}-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine …
PLN-74809
PLN-74809 is a small-molecule that dually inhibits both αvβ6 and αvβ1 to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) . The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in...
Investigational
Matched Description: … are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 …
BI-765063
BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).
Investigational
Taurochenodeoxycholic acid
Taurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile. As a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile...
Experimental
Displaying drugs 2951 - 2975 of 4316 in total